日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus

高scFv受体亲和力并不能增强HER2靶向麻疹病毒的抗肿瘤活性

Suksanpaisan, L; Russell, S J; Peng, K-W

Oral contrast enhances the resolution of in-life NIS reporter gene imaging

口服造影剂可提高活体NIS报告基因成像的分辨率

Suksanpaisan, L; Pham, L; McIvor, S; Russell, S J; Peng, K-W

Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV

脑膜骨髓瘤沉积物会对溶瘤性大疱性口炎病毒(VSV)的治疗指数产生不利影响。

Yarde, D N; Naik, S; Nace, R A; Peng, K-W; Federspiel, M J; Russell, S J

Curative one-shot systemic virotherapy in murine myeloma

小鼠骨髓瘤的单次全身病毒疗法治愈

Naik, S; Nace, R; Federspiel, M J; Barber, G N; Peng, K-W; Russell, S J

Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.

聚肌苷酸可减少麻疹病毒的隔离,并改善其全身治疗效果

Liu Y-P, Tong C, Dispenzieri A, Federspiel M J, Russell S J, Peng K-W

Dynamics of multiple myeloma tumor therapy with a recombinant measles virus

重组麻疹病毒治疗多发性骨髓瘤肿瘤的动态变化

Dingli, D; Offord, C; Myers, R; Peng, K-W; Carr, T W; Josic, K; Russell, S J; Bajzer, Z

Measles virus for cancer therapy

麻疹病毒用于癌症治疗

Russell, S J; Peng, K W

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

静脉注射溶瘤性麻疹病毒 MV-NIS(联合或不联合环磷酰胺给药)的临床前药理学和毒理学研究

Myers, R M; Greiner, S M; Harvey, M E; Griesmann, G; Kuffel, M J; Buhrow, S A; Reid, J M; Federspiel, M; Ames, M M; Dingli, D; Schweikart, K; Welch, A; Dispenzieri, A; Peng, K-W; Russell, S J